Skip to Content

Primidone Pregnancy and Breastfeeding Warnings

Primidone is also known as: Mysoline

Primidone Pregnancy Warnings

Neonatal hemorrhage has been reported in newborns whose mothers were taking primidone and other and other anticonvulsants. Therefore, prophylactic administration of vitamin K1 therapy for one month prior to and during delivery is recommended for pregnant women on anticonvulsant therapy. To provide information regarding the effects of in utero exposure to primidone, physicians are advised to recommend that pregnant patients taking primidone enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website

Primidone has not been assigned to a pregnancy category by the FDA. Animal studies on primidone have shown palatal clefting to be the most common defect and to be dose related. There are no controlled data in human pregnancy. An association has been suggested between the use of use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in the children born to these women. Because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life, the manufacturer has stated that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures. Alternatively, if the severity and frequency of the seizure disorders is felt to be such that removal of the drug is not believed to pose a serious threat to the patient, then discontinuation of the drug may be considered prior to and during pregnancy. The danger of the medication should be weighed against the possibility that even minor seizures may pose a hazard to the developing embryo or fetus.

See references

Primidone Breastfeeding Warnings

Primidone is excreted into human milk in substantial amounts. The manufacturer states that the presence of undue somnolence and drowsiness in nursing newborns of primidone treated mothers is as an indication that nursing should be discontinued.

See references

References for pregnancy information

  1. "Product Information. Mysoline (primidone)" Elan Pharmaceuticals, S. San Francisco, CA.
  2. Myhre SA, Williams R "Teratogenic effects associated with maternal primidone therapy." J Pediatr 99 (1981): 160-2

References for breastfeeding information

  1. "Product Information. Mysoline (primidone)" Elan Pharmaceuticals, S. San Francisco, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.